Steve Bryson, PhD,  science writer—

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

CAD treatment riliprubart may be given every 3 months: Study

Riliprubart (SAR445088), a potential successor to Enjaymo (sutimlimab-jome) as a cold agglutinin disease (CAD) treatment, may achieve therapeutic levels with every-three-month dosing at a fixed dose. That’s according to a study that used modeling tools to analyze available clinical trial data and propose an optimal dosing regimen for…

Cold agglutinins linked to lung transplant complications: Study

Nearly half of people without symptoms of cold agglutinin disease (CAD) who undergo a lung transplant test positive for cold agglutinins, the self-reactive antibodies that drive the rare autoimmune condition by targeting red blood cells at low temperatures. That’s according to new data from the first study of its kind…

FACIT-Fatigue questionnaire reliable CAD measure, study finds

The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale, a widely used questionnaire to assess fatigue, is reliable, valid, and responsive to changes in the severity of cold agglutinin disease (CAD), according to a study. The findings relied on CAD patients’ impressions of the FACIT-Fatigue scale and data from…

ANX1502 tablet shows promise in proof-of-concept CAD trial

Annexon Biosciences’ new tablet formulation of its experimental therapy ANX1502 reduced key clinical and biomarker measures in the three cold agglutinin disease (CAD) patients so far enrolled in a proof-of-concept clinical trial. “In patients treated with the oral small molecule ANX1502, we are encouraged by the changes in…

Uncommon cellular process in blood may help make AIHA diagnosis

Nearly half of children and teens with autoimmune hemolytic anemia (AIHA) — a group of disorders that includes cold agglutinin disease (CAD)  — have signs of erythrophagocytosis, or the removal of old and damaged red blood cells by immune cells, in blood samples, a small study shows. While erythrophagocytosis…

Case study notes challenges to CAD diagnosis, care in Pakistan

Researchers said a case of cold agglutinin disease (CAD) in a 92-year-old man in Pakistan illustrates the challenges of CAD diagnosis and management in developing countries. The man’s experience highlights “the urgent need to improve healthcare infrastructure and enhance diagnostic capabilities while facilitating equitable access to essential CAD treatments…

Woman develops CAD secondary to thyroid cancer: Case report

A 50-year-old woman developed cold agglutinin disease (CAD) secondary to two different types of cancer within the thyroid gland, a study reported. The surgical removal of the thyroid gland successfully treated both the cancer and CAD. While CAD has been reported to occur secondary to blood cancers, it is…

Erythropoietin effective for anemia in CAD patients: Study in Italy

Treatment with erythropoietin (EPO), a hormone that stimulates red blood cell production, safely increases hemoglobin levels in adults with cold agglutinin disease (CAD) and other autoimmune hemolytic anemias (AIHAs), according to a single-center study in Italy. Data show the treatment was effective in patients with abnormally low levels…